Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Completion of Patient Enrollment in the Phase 2 Portion of the DFP-17729 Phase 2/3 Comparative Trial
Subject Entity
Delta-Fly Pharma株式会社, NIPPON CHEMIPHAR CO.,LTD.
Target Locations / Products
DFP-17729, an agent that improves the tumor microenvironment, and a Phase 2/3 comparative trial for third-line or later treatment of pancreatic cancer
Awareness or receipt of notice28 May 2026 (the date on which the Company was notified by a participating clinical trial site that patient enrollment had been completed)
This disclosure05/28/2026
Outlook
The number of patients in the Phase 3 portion will be increased or decreased depending on the superiority of overall survival (OS) in the Phase 2 portion, and the Company will proceed promptly to the Phase 3 portion.
| Item | Details |
|---|---|
| Event name | Completion of Patient Enrollment in the Phase 2 Portion of the DFP-17729 Phase 2/3 Comparative Trial |
| Date recognized / date notice received | 28 May 2026 (the date on which the Company was notified by a participating clinical trial site that patient enrollment had been completed) |
| Subject Entity | Delta-Fly Pharma株式会社, NIPPON CHEMIPHAR CO.,LTD. |
| Target Locations / Products | DFP-17729, an agent that improves the tumor microenvironment, and a Phase 2/3 comparative trial for third-line or later treatment of pancreatic cancer |
| Outlook | The number of patients in the Phase 3 portion will be increased or decreased depending on the superiority of overall survival (OS) in the Phase 2 portion, and the Company will proceed promptly to the Phase 3 portion. |
Items this document does not state (20)
Date of occurrenceCauseAmount of Impact on Business PerformanceAccounting period in which recognizedImpact on Earnings ForecastType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company was notified by participating clinical trial sites that patient enrollment had been completed.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.